cenegermin
Sign in to saveCenegermin, sold under the brand name Oxervate, also known as recombinant human nerve growth factor, is a recombinant form of human nerve growth factor. Cenegermin is a peripherally selective agonist of the tropomyosin receptor kinase A (TrkA) and low-affinity nerve growth factor receptor (p75NTR).
Clinical Trials
10 registered- COMPLETEDNerve Growth Factor for the Treatment of Cornea DiseaseStanford University · NCT04552730
- PHASE4COMPLETEDStudy to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic KeratitisDompé Farmaceutici S.p.A · NCT04485546
- COMPLETEDCorneal Nerves After Treatment With CenegerminUniversity of California, Los Angeles · NCT04627571
- PHASE3RECRUITINGAn Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCEDDompé Farmaceutici S.p.A · NCT07519902
- PHASE4ACTIVE_NOT_RECRUITINGDOMPE -MT Neurotrophic KeratitisToyos Clinic · NCT06947850
- PHASE3NOT_YET_RECRUITINGEfficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)Dompé Farmaceutici S.p.A · NCT07453888
~1 min read
Encyclopedic overview
5 sectionsContents
- Medical uses
- Society and culture
- Names
- References
- Further reading
Cenegermin, sold under the brand name Oxervate, also known as recombinant human nerve growth factor, is a recombinant form of human nerve growth factor. Cenegermin is a peripherally selective agonist of the tropomyosin receptor kinase A (TrkA) and low-affinity nerve growth factor receptor (p75NTR).
The most common side effects include eye pain and inflammation, increased lacrimation (watery eyes), pain in the eyelid and sensation of a foreign body in the eye.
Excerpted from Wikipedia’s “cenegermin” article, available under the CC BY-SA 4.0 licence.